Biogen slashes price of controversial Alzheimer's drug

US-based Biogen has dropped the price of its Alzheimer's treatment Aduhelm by fifty percent, Bloomberg News reports.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Biogen's Aduhelm rejected by EMA committee
For subscribers